Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) had its price target lowered by analysts at D. Boral Capital from $15.00 to $8.00. They now have a "buy" rating on the stock.
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Reviva to Participate in the 2025 BIO CEO & Investor Conference